Aurobindo Pharma Ltd

Aurobindo Pharma will hold a meeting of the Board of Directors of the Company on 9 February 2026.Powered by Capital Market - Live

Aurobindo Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 1187.9, up 3.24% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.5% on the day, quoting at 25293. The Sensex is at 82170.1, down 0.48%. Aurobindo Pharma Ltd has gained around 0.41% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has gained around 4.67% in last one month and is currently quoting at 21564, up 0.46% on the day. The volume in the stock stood at 49.13 lakh shares today, compared to the daily average of 8.28 lakh shares in last one month. The benchmark February futures contract for the stock is quoting at Rs 1187.9, up 3.04% on the day. Aurobindo Pharma Ltd is up 1.37% in last one year as compared to a 7.59% jump in NIFTY and a 1.05% jump in the Nifty Pharma index.The PE of the stock is 33.07 based on TTM earnings ending September 25.Powered by Capital Market - Live

Ramkrishna Forgings Ltd, Leela Palaces Hotels & Resorts Ltd, Narayana Hrudayalaya Ltd, Craftsman Automation Ltd are among the other stocks to see a surge in volumes on BSE today, 30 January 2026.Aurobindo Pharma Ltd clocked volume of 5.81 lakh shares by 10:46 IST on BSE, a 53.98 times surge over two-week average daily volume of 10754 shares. The stock gained 2.13% to Rs.1,175.00. Volumes stood at 13339 shares in the last session.Ramkrishna Forgings Ltd notched up volume of 4.2 lakh shares by 10:46 IST on BSE, a 28.34 fold spurt over two-week average daily volume of 14831 shares. The stock rose 2.07% to Rs.518.10. Volumes stood at 6978 shares in the last session.Leela Palaces Hotels & Resorts Ltd witnessed volume of 14.11 lakh shares by 10:46 IST on BSE, a 27.8 times surge over two-week average daily volume of 50757 shares. The stock increased 1.29% to Rs.406.75. Volumes stood at 3.08 lakh shares in the last session.Narayana Hrudayalaya Ltd registered volume of 2.13 lakh shares by 10:46 IST on BSE, a 9.06 fold spurt over two-week average daily volume of 23486 shares. The stock rose 1.79% to Rs.1,774.30. Volumes stood at 9677 shares in the last session.Craftsman Automation Ltd registered volume of 21129 shares by 10:46 IST on BSE, a 8.13 fold spurt over two-week average daily volume of 2598 shares. The stock rose 0.55% to Rs.7,348.45. Volumes stood at 2893 shares in the last session.Powered by Capital Market - Live

Khandelwal Laboratories operates in India's pharmaceutical industry with a presence in both oncology and non-oncology branded formulations. The non-oncology portfolio comprises 23 brands across 67 stock-keeping units (SKUs), along with nine products in the pipeline where anti-infective as well as pain management are the major portfolios. The business generated a turnover of Rs 113.53 crore in FY2024-25 with an EBITDA of Rs 28.99 crore. The transaction was signed and completed on 1 January 2026. Under the agreement, Auro Pharma has acquired the branded non-oncology prescription formulations business of Khandelwal Laboratories as a going concern on a slump-sale basis. The acquisition includes inventory, intellectual property, employees, contracts, and other associated assets. The total cash consideration for the transaction is Rs 325 crore. The acquisition is expected to strengthen the company's pain management and anti-infective portfolio, complementing its existing offerings and supporting expansion in the domestic market. Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company's consolidated net profit increased 3.8% to Rs 848.45 crore on 7.7% increase in net sales to Rs 8,236.96 crore in Q2 FY26 over Q2 FY25.Powered by Capital Market - Live

Auro Pharma (Auro Pharma), a wholly owned subsidiary of Aurobindo Pharma at its meeting held today i.e. 01 January 2026 has approved the acquisition of non-oncology prescription formulations business of Khandelwal Laboratories on a going concern basis through a Business Transfer Agreement (BTA). Powered by Capital Market - Live

Aurobindo Pharma announced that pending receipt of state government approval for setting up a captive solar power plant, the required investment for acquiring 26% in Swarnaakshu Solar Power will be completed on or before 31 March 2026, subject to the receipt of approval from the concerned state government. Powered by Capital Market - Live

Aurobindo Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 1198.8, down 0.61% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.36% on the day, quoting at 25948.55. The Sensex is at 84699.55, down 0.4%.Aurobindo Pharma Ltd has eased around 1.43% in last one month.Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has eased around 1.26% in last one month and is currently quoting at 22684.65, down 0.37% on the day. The volume in the stock stood at 2.55 lakh shares today, compared to the daily average of 6.38 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 1202.3, down 0.37% on the day. Aurobindo Pharma Ltd tumbled 7.66% in last one year as compared to a 9.74% rally in NIFTY and a 2.76% fall in the Nifty Pharma index.The PE of the stock is 34.66 based on TTM earnings ending September 25.Powered by Capital Market - Live

Aurobindo Pharma announced that the United States Food and Drug Administration (US FDA) inspected Unit-IV of APL Healthcare, a wholly owned subsidiary of the Company, situated at Palchur village and part of Palepalem Village Naidupeta Mandal, SPSR Nellore District, 524126, Andhra Pradesh, from 08 December to 17 December 2025. At the end of the current inspection, a 'Form 483' was issued with 05 observations which are procedural in nature, and we will respond to the US FDA within the stipulated timelines. Powered by Capital Market - Live

The inspection was conducted from 8 December to 17 December 2025. At the end of the current inspection, a 'Form 483' was issued with 5 observations which are procedural in nature, and the company said that it will respond to the US FDA within the stipulated timelines. Aurobindo Pharma is principally engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. The company's consolidated net profit increased 3.8% to Rs 848.45 crore on 7.7% increase in net sales to Rs 8,236.96 crore in Q2 FY26 over Q2 FY25. The scrip rose 0.36% to Rs 1,197.40 on the BSE.Powered by Capital Market - Live

Aurobindo Pharma Ltd is up for a fifth straight session today. The stock is quoting at Rs 1218.8, up 0.71% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.26% on the day, quoting at 25811.05. The Sensex is at 84221.24, down 0.3%. Aurobindo Pharma Ltd has gained around 9.9% in last one month. Meanwhile, Nifty Pharma index of which Aurobindo Pharma Ltd is a constituent, has gained around 3.23% in last one month and is currently quoting at 22686.8, up 0.36% on the day. The volume in the stock stood at 10.7 lakh shares today, compared to the daily average of 13.98 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 1223.1, up 0.95% on the day. Aurobindo Pharma Ltd is down 1.34% in last one year as compared to a 10.05% jump in NIFTY and a 5.69% jump in the Nifty Pharma index.The PE of the stock is 35.05 based on TTM earnings ending September 25.Powered by Capital Market - Live